Moreover, due to the cancer- and lineage-specific expression pattern of lncRNAs, a group of lncRNAs have proven to be prospective biomarkers, e.g., PCA3 and PCAT14 in prostate cancer (Chun et al., 2009; Shukla et al., 2016), which could be used for the early detection, diagnosis, and follow-up in the clinic. This evidence concerns the gene PCAT14 and prostate carcinoma.